

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

IVD 994

U. S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/446601

INTERNATIONAL APPLICATION NO.
PCT/FR98/01285 ✓INTERNATIONAL FILING DATE
19 June 1998 ✓PRIORITY DATE CLAIMED
23 June 1997 ✓TITLE OF INVENTION **Solid Pharmaceutical Composition Containing Benzofuran Derivatives** ✓

APPLICANT(S) FOR DO/EO/US

Bernard ABRAMOVICI, Jean-Claude GAUTIER, Jean-Claude GROMENIL, Jean-Marie MARRIER ✓

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND or SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1)).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371 (c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An unexecuted oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
Citation of References

FORM PTO-1390 (REV 10-95) page 2 of 2



9 / 446601

418 Rec'd PCT/PTO 22 DEC 1999

Application of: Bernard ABRAMOVICI, Jean-Claude GAUTIER, Jean-Claude GROMENIL and Jean-Marie MARRIER

Docket No.: IVD 994

Filing Under 35 U.S.C. § 371

Filed As a U.S. National Phase Application of
International Application Serial No. PCT/FR98/01285
Filed 16 June 1998

FOR: **SOLID PHARMACEUTICAL COMPOSITION
CONTAINING BENZOFURAN DERIVATIVES**

CERTIFICATE UNDER 37 C.F.R. 1.10

Express Mail Label No.: EL301242810US

Date of Deposit: December 22, 1999

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above, and is addressed to:

Asst. Commissioner for Patents, Box PCT, Attn: EO/US, Washington, DC 20231

Dany L. Bean

Signature

09/446601
428 Rec'd PCT/PTO 22 DEC 1999

ENGLISH TRANSLATION OF INTERNATIONAL PATENT
APPLICATION PCT/FR98/01285
filed on 16 June 1998
in the name of SANOFI

CERTIFICATE UNDER 37 C.F.R. 1.10

Express Mail Label No.: EL301242810US

Date of Deposit: December 22, 1999

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above, and is addressed to:

Asst. Commissioner for Patents, Box PCT, Attn: EO/US,
Washington, DC 20231

Amey L. Beau
Signature